Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data

Ibrahim Tohidi-Esfahani, MBBS,FRACP,FRCPA, Andrew Warden, Elena Malunis, Peter Liburdi deNardis, Javier Haurat, Marita Black, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Shirley D'Sa, MD FRCPath, Marie José Kersten, MD PhD, Ruth Spearing, MD, Maria Lia Palomba, Adam J Olszewski, MD, Carl Harrington, Clare Scott, MBBS PhDFRACP, Judith Trotman, FRACP

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-138945

Published: 2020

Journal Articles

Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136236

Published: 2020

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Laurie H. Sehn, MDMPH, Mark Hertzberg, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Alex F. Herrera, MD, Sarit E Assouline, MD MSc, Christopher Flowers, MDMS, Tae Min Kim, MD PhD, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, MD PhD, Lisa Musick, Jamie Hirata, YiMeng Chang, Grace Ku, Matthew J Matasar, MD

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-137078

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134280

Published: 2020

Journal Articles

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Michael Wang, MD, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Javier Munoz, MD, Tycel J. Phillips, MD, Won-Seog Kim, MD PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Judith Trotman

Blood (2018) 132 (Supplement 1): 1592.

https://doi.org/10.1182/blood-2018-99-117224

Published: 2018

Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD

Blood (2015) 126 (23): 832.

https://doi.org/10.1182/blood.V126.23.832.832

Published: 2015

Journal Articles

Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression

Sumita Ratnasingam, MBBS, Patricia A. Walker, MBBS, Huy Tran, MBBS, Zane Kaplan, MD, James David McFadyen, MD, Huyen Tran, MD, Tse-Chieh Teh, MD, Erica M. Wood, MD, John V. Catalano, MD, Stephen Opat, MBBS, Jake Shortt, MD

Blood (2015) 126 (23): 3457.

https://doi.org/10.1182/blood.V126.23.3457.3457

Published: 2015

Journal Articles

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Chan Y Cheah, MBBS, FRACP, FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Kacey O'Rourke, MBBS FRACP FRCPA, Glen Kennedy, MBBS FRACP FRCPA, Anupkumar George, MBBS FRACP FRCPA, Pasquale Fedele, MBBS, Shuh Ying Tan, MBBS, Stephen Opat, MBBS(Hons) FRACP FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S. Tam, MBBS, FRACP, FRCPA, MD, John F Seymour, MBBS, PhD, FRACP

Blood (2013) 122 (21): 4353.

https://doi.org/10.1182/blood.V122.21.4353.4353

Published: 2013

Journal Articles

Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study

Stephen Opat, MBBS(Hons) FRACP FRCPA, Robert Bird, MD, Cecily J Forsyth, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Constantine S. Tam, MBBS, FRACP, FRCPA, Penelope Motum, MB BS PhD FRACP FRCPA, Mark A. Bentley, MBBS FRCPA FRACP

Blood (2011) 118 (21): 5050.

https://doi.org/10.1182/blood.V118.21.5050.5050

Published: 2011

Journal Articles

Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).

Pedro Farinha, MD, Stephen Opat, MBBS, Merrill Boyle, Nathalie Johnson, MD, Hilary O'Leary, MD, Lin Wang, MD, James R. Cook, MD, PhD, Raymond R. Tubbs, DO, Joseph M. Connors, MD, Randy D. Gascoyne, MD

Blood (2009) 114 (22): 3944.

https://doi.org/10.1182/blood.V114.22.3944.3944

Published: 2009

Journal Articles

The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.

Stephen Opat, MBBS, Pedro Farinha, MD, Merrill Boyle, Nathalie Johnson, MD, Hilary OLeary, MD, James R. Cook, MD, PhD, Raymond R. Tubbs, DO, Lin Wang, MD, Ryan Woods, Joseph M. Connors, MD, Randy D. Gascoyne

Blood (2009) 114 (22): 2923.

https://doi.org/10.1182/blood.V114.22.2923.2923

Published: 2009

NARROW

Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data

Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study

Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).

The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only